Lupin moves up on getting USFDA`s nod for Emtricitabine and Tenofovir Alafenamide Tablets
Lupin is currently trading at Rs. 2116.45, up by 17.75 points or 0.85% from its previous closing of Rs. 2098.70 on the BSE.
The scrip opened at Rs. 2098.05 and has touched a high and low of Rs. 2126.85 and Rs. 2080.10 respectively. So far 15741 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2312.00 on 05-Sep-2024 and a 52 week low of Rs. 1200.35 on 21-Dec-2023.
Last one week high and low of the scrip stood at Rs. 2126.85 and Rs. 2040.00 respectively. The current market cap of the company is Rs. 96551.93 crore.
The promoters holding in the company stood at 46.96%, while Institutions and Non-Institutions held 46.60% and 6.44% respectively.
Lupin has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Emtricitabine and Tenofovir Alafenamide Tablets, 200 mg/25 mg, to market a generic equivalent of Descovy Tablets, 200 mg/25 mg of Gilead Sciences, Inc. Lupin is one of the first ANDA applicants and is eligible for 180 days of shared generic exclusivity. This product will be manufactured at Lupin’s Nagpur facility in India.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
